ITCMDBv1
Clinical TrialID 7499

A Safety and Efficacy Study of Hymecromone Tablets for the Treatment of Patients With COVID-19.

NCT05386420

COVID-19

Back to Browse

Relationship Network

Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.

Click a node to open it in a new tab
Trial: 1Ingredient: 1Links: 1
Arranging relationship network...

Record Fields

Scalar fields from the final clinical_trial record.

Clinical Trial Id
7499
Evidence Id
7499
Core Evidence Id
7499
Source Clinical Trial Id
7494
Herb2 Clinical Trial Id
HBCT007494
Nct Id
NCT05386420
Title
A Safety and Efficacy Study of Hymecromone Tablets for the Treatment of Patients With COVID-19.
Status
Phase
Study Result
No
Study Condition
COVID-19
Study Type
Interventional
Study Design
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
Intervention
DRUG: Hymecromone tablets|OTHER: Placebo
Intervention Allocation
Randomized
Intervention Model
Parallel
Intervention Mask
Double
Intervention Purpose
Treatment
Gender
All
Age
Adult, Older_Adult
Enrollment
304
Outcome Measure
The proportion of subjects who developed disease progression., To compare the proportion of subjects in the experimental group and the control group who developed disease progression within 28 days after initial treatment., Within 28 days after initial treatment.
Sponsor Collaborator
Shanghai Zhongshan Hospital
Funded By
OTHER
Location
Zhong Shan Hospital affiliated to Fudan University, Shanghai, Shanghai, 200030, China
Other Id
QJXDS-22-01
Start Date
2022-05-23
Primary Completion Date
2022-08-15
Completion Date
2022-11-15
First Posted
2022-05-23
Results First Posted
Last Update Posted
2022-06-09
Study Document
Study Url
https://clinicaltrials.gov/study/NCT05386420
Title Cn
Title En
A Safety and Efficacy Study of Hymecromone Tablets for the Treatment of Patients With COVID-19.
Bilingual Status
semi_complete